Compare NextEra Energy, Inc. (NEE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sana Biotechnology Inc — how do they compare? NextEra Energy, Inc. trades at $87.99 (market cap $183.53B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: NextEra Energy, Inc. is far larger — about 210× Sana Biotechnology Inc's market cap, and NextEra Energy, Inc. pays a 2.83% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NEE | SANA | |
|---|---|---|
Market Cap | $183.53B | $873.84M |
Sector | Utilities | Health |
52-Week High | $97.88 | $5.92 |
52-Week Low | $69.77 | $2.68 |
Enterprise Value | $285.94B | $848.03M |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $87.93, down 0.98% with a bearish technical signal. The company shows strong profitability with 29.37% net margin and 15.58% ROE, though Q4 2025 earnings missed expectations. Recent news highlights the proposed Dominion Energy combination and $59 billion capital expenditure plan through 2032. Analyst consensus remains strongly bullish with 66.7% buy ratings and $101.88 price target, representing 16% upside potential.
NEE offers solid long-term growth prospects from renewable energy expansion and regulatory advantages, but faces execution risks from massive capital spending and integration challenges from the Dominion merger. Current valuation at 22.34 P/E appears reasonable given growth trajectory, though technical weakness suggests near-term consolidation may continue before potential breakout.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
